1.76

2.33% +0.04

iBio Inc (IBIO)

Overview News Price History Option Chain Why IBIO Down? Discussions Forecast Stock Split

iBio Inc stock is currently priced at $1.76, with a 24-hour trading volume of 51,782. It has seen a +2.33% increased in the last 24 hours and a +53.04% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.77 pivot point. If it approaches the $1.63 support level, significant changes may occur.

Previous Close:

$1.72

Open:

$1.77

24h Volume:

51,782

Market Cap:

$15.05M

Revenue:

$2.05M

Net Income/Loss:

$-27.28M

P/E Ratio:

-0.3056

EPS:

-5.76

Net Cash Flow:

$-18.89M

1W Performance:

+2.33%

1M Performance:

+53.04%

6M Performance:

+502.12%

1Y Performance:

+61.47%

1D Range:

$1.72

$1.77

52W Range:

$0.20

$4.98

iBio Inc Stock (IBIO) Company Profile

Name

iBio Inc

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

302-355-0650

Address

600 Madison Avenue, Suite 1601, New York, NY

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

IBIO's Discussions on Twitter

iBio Inc Stock (IBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-29-21	Initiated	JMP Securities	Mkt Outperform
Jan-22-21	Initiated	Cantor Fitzgerald	Overweight
Jun-26-20	Initiated	Alliance Global Partners	Buy

iBio Inc Stock (IBIO) Latest News

Balancing Volatility With Stability When Trading Penny Stocks

PennyStocks

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

GlobeNewswire Inc.

iBio Inc Stock (IBIO) Financials Data

iBio Inc (IBIO) Revenue 2024

IBIO reported a revenue (TTM) of $2.04 million for the quarter ending September 30, 2021.

iBio Inc (IBIO) Net Income 2024

IBIO net income (TTM) was -$27.28 million for the quarter ending December 31, 2023, a +66.41% increase year-over-year.

iBio Inc (IBIO) Cash Flow 2024

IBIO recorded a free cash flow (TTM) of -$18.89 million for the quarter ending December 31, 2023, a +62.21% increase year-over-year.

iBio Inc (IBIO) Earnings per Share 2024

IBIO earnings per share (TTM) was -$15.02 for the quarter ending December 31, 2023, a +91.52% growth year-over-year.

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.